| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Clara Bernardelli, Eloisa Chiaramonte, Silvia Ancona, Silvia M Sirchia, Amilcare Cerri, Elena Lesm. Primary TSC2 International journal of molecular sciences. vol 23. issue 17. 2022-09-09. PMID:36077111. |
primary tsc2 cutaneous lesions are one of the hallmarks of tuberous sclerosis complex (tsc), a genetic disease in which mtor is hyperactivated due to the lack of hamartin or tuberin. |
2022-09-09 |
2023-08-14 |
Not clear |
| Alfredo Cerisola, Lucía Cibils, María Eugenia Chaibún, Virginia Pedemonte, Melania Rosa. [Tuberous sclerosis complex: diagnosis and current treatment]. Medicina. vol 82 Suppl 3. 2022-09-02. PMID:36054862. |
tuberous sclerosis complex is an autosomal dominant genetic multisystemic disorder caused primarily by mutations in one of the two tumor suppressor genes tsc1 or tsc2, resulting in increased activation of the mtor pathway. |
2022-09-02 |
2023-08-14 |
Not clear |
| Mehmet E Adin, David Durand, William B Zucconi, Anita J Huttner, Dennis D Spencer, Richard A Brone. Diagnostic and interventional radiology (Ankara, Turkey). 2022-08-23. PMID:35997478. |
for instance, it has been recently found that focal cortical dysplasia iib, tuberous sclerosis, hemimegalencephaly, and gangliogliomas are all the result of mutations of the mtor pathway for cell growth. |
2022-08-23 |
2023-08-14 |
Not clear |
| Paolo Curatolo, Nicola Specchio, Eleonora Aronic. Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy. The Lancet. Neurology. vol 21. issue 9. 2022-08-13. PMID:35963265. |
tuberous sclerosis complex is a rare genetic disease associated with mutations in the tsc1 or tsc2 genes, which cause overactivation of the mtor complex. |
2022-08-13 |
2023-08-14 |
Not clear |
| Paolo Curatolo, Nicola Specchio, Eleonora Aronic. Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy. The Lancet. Neurology. vol 21. issue 9. 2022-08-13. PMID:35963265. |
the scope for mitigation of tuberous sclerosis complex-associated symptoms has expanded, including the use of mtor inhibitors such as sirolimus and everolimus. |
2022-08-13 |
2023-08-14 |
Not clear |
| Vasiliki Karalis, Franklin Caval-Holme, Helen S Bateu. Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex. Nature communications. vol 13. issue 1. 2022-08-09. PMID:35945201. |
tuberous sclerosis complex (tsc) is a neurodevelopmental disorder caused by mutations in the tsc1 or tsc2 genes, which encode proteins that negatively regulate mtor complex 1 (mtorc1) signaling. |
2022-08-09 |
2023-08-14 |
mouse |
| Pedram Argani, Andres Matoso, Aparna Pallavajjalla, Lisa Haley, Ming Tseh-Lin, Jessica Ng, C W Chow, Tamara Lotan, Rohit Mehr. Xanthomatous Giant Cell Renal Cell Carcinoma: Another Morphologic Form of TSC-associated Renal Cell Carcinoma. The American journal of surgical pathology. 2022-08-08. PMID:35941720. |
over the past decade, several distinct novel renal epithelial neoplasms driven by underlying tuberous sclerosis comples (tsc)/mammalian target of rapamycin (mtor) pathway mutations have been described. |
2022-08-08 |
2023-08-14 |
Not clear |
| Paul A Roberson, Leonard S Jefferson, Scot R Kimbal. Convergence of Signaling Pathways in Mediating Actions of Leucine and IGF-1 on mTORC1 in L6 Myoblasts. American journal of physiology. Cell physiology. 2022-08-01. PMID:35912992. |
compared to leucine- and serum-deprived myoblasts, igf-1, but not leucine, promoted phosphorylation of protein kinase b (akt), tuberous sclerosis complex 2 (tsc2), and the autophosphorylation site on mtor (s2481) and also stimulated mtor kinase activity in mtor immunoprecipitated samples. |
2022-08-01 |
2023-08-14 |
Not clear |
| Rohan R Shah, W Clark Lambert, Robert A Schwart. Birt-Hogg-Dubé Syndrome: Another mTOR Phenomenon. Clinics in dermatology. 2022-07-30. PMID:35907578. |
like tuberous sclerosis, bhds's clinical features may subside with the use of oral rapamycin for mtor inhibition, a theoretical concept meriting exploration. |
2022-07-30 |
2023-08-14 |
Not clear |
| Luyang Han, Yuting Wu, Fangming Liu, Hongbing Zhan. eIF4A1 Inhibitor Suppresses Hyperactive mTOR-Associated Tumors by Inducing Necroptosis and G2/M Arrest. International journal of molecular sciences. vol 23. issue 13. 2022-07-09. PMID:35805935. |
we tested the potential of eft226, a sequence-selective inhibitor of eif4a-mediated translation, in the treatment of mtor hyperactive cells caused by the deletion of tuberous sclerosis complex 1/2 (tsc1/2) or phosphatase and tensin homology (pten). |
2022-07-09 |
2023-08-14 |
Not clear |
| Femke V M Mulder, Evelien F H I Peeters, Jan Westerink, Fried J T Zwartkruis, Wendela L de Ranitz-Greve. The long-term effect of mTOR inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the Dutch TSC registry. Orphanet journal of rare diseases. vol 17. issue 1. 2022-07-08. PMID:35804402. |
the long-term effect of mtor inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the dutch tsc registry. |
2022-07-08 |
2023-08-14 |
Not clear |
| Femke V M Mulder, Evelien F H I Peeters, Jan Westerink, Fried J T Zwartkruis, Wendela L de Ranitz-Greve. The long-term effect of mTOR inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the Dutch TSC registry. Orphanet journal of rare diseases. vol 17. issue 1. 2022-07-08. PMID:35804402. |
mtor inhibition is an effective treatment for many manifestations of tuberous sclerosis complex. |
2022-07-08 |
2023-08-14 |
Not clear |
| Guangxu Bai, Hao Wang, Na Cu. mTOR pathway mediates endoplasmic reticulum stress-induced CD4 Apoptosis : an international journal on programmed cell death. 2022-06-27. PMID:35759162. |
hence, in this study, a classical cecal ligation and puncture (clp) sepsis model was constructed by using the t cell-specific knockout mtor and tsc1 (tuberous sclerosis complex, the inhibitor of mtor signaling pathway) mice to explore the underlying signaling pathway and molecular mechanism of host immune imbalance caused by apoptosis in sepsis. |
2022-06-27 |
2023-08-14 |
mouse |
| Bartłomiej Pawlik, Urszula Smyczyńska, Szymon Grabia, Wojciech Fendler, Izabela Dróżdż, Katarzyna Bąbol-Pokora, Katarzyna Kotulska, Sergiusz Jóźwiak, Julita Borkowska, Wojciech Młynarski, Joanna Trelińsk. mTOR Inhibitor Treatment in Patients with Tuberous Sclerosis Complex Is Associated with Specific Changes in microRNA Serum Profile. Journal of clinical medicine. vol 11. issue 12. 2022-06-24. PMID:35743464. |
mtor inhibitor treatment in patients with tuberous sclerosis complex is associated with specific changes in microrna serum profile. |
2022-06-24 |
2023-08-14 |
Not clear |
| Ines Serra, Ana Stravs, Catarina Osório, Maria Roa Oyaga, Martijn Schonewille, Christian Tudorache, Aleksandra Badur. Frontiers in molecular neuroscience. vol 15. 2022-06-01. PMID:35645731. |
tuberous sclerosis complex 1 (tsc1) is a tumor suppressor that promotes the inhibition of mechanistic target of rapamycin (mtor) pathway, and mutations in |
2022-06-01 |
2023-08-13 |
Not clear |
| Dominique F Leitner, Evgeny Kanshin, Manor Askenazi, Yik Siu, Daniel Friedman, Sasha Devore, Drew Jones, Beatrix Ueberheide, Thomas Wisniewski, Orrin Devinsk. Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia. PloS one. vol 17. issue 5. 2022-05-19. PMID:35587487. |
tuberous sclerosis complex (tsc) and some focal cortical dysplasias (fcds) are associated with dysfunctional mtor signaling, resulting in increased cell growth and ribosomal s6 protein phosphorylation (phospho-s6). |
2022-05-19 |
2023-08-13 |
Not clear |
| Sandra Schrötter, Christopher J Yuskaitis, Michael R MacArthur, Sarah J Mitchell, Aaron M Hosios, Maria Osipovich, Margaret E Torrence, James R Mitchell, Gerta Hoxhaj, Mustafa Sahin, Brendan D Mannin. The non-essential TSC complex component TBC1D7 restricts tissue mTORC1 signaling and brain and neuron growth. Cell reports. vol 39. issue 7. 2022-05-18. PMID:35584673. |
the tuberous sclerosis complex (tsc) 1 and 2 proteins associate with tbc1d7 to form the tsc complex, which is an essential suppressor of mtor complex 1 (mtorc1), a ubiquitous driver of cell and tissue growth. |
2022-05-18 |
2023-08-13 |
mouse |
| Yasutaka Okita, Maiko Yoshimura, Yoshinori Katada, Yukihiko Saeki, Shiro Ohshim. A Mechanistic Target of Rapamycin (mTOR) Inhibitor, Everolimus Safely Ameliorated Lupus Nephritis in a Patient Complicated with Tuberous Sclerosis. Modern rheumatology case reports. 2022-05-05. PMID:35512453. |
a mechanistic target of rapamycin (mtor) inhibitor, everolimus safely ameliorated lupus nephritis in a patient complicated with tuberous sclerosis. |
2022-05-05 |
2023-08-13 |
Not clear |
| Yu-Ting Lin, Chia-Ling Yu, Yu-Kang Tu, Ching-Chi Ch. Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis. Biomedicines. vol 10. issue 4. 2022-04-23. PMID:35453576. |
previous studies have suggested that the topical mechanistic target of rapamycin (mtor) inhibitors may be effective in treating facial angiofibromas in patients with tuberous sclerosis complex (tsc). |
2022-04-23 |
2023-08-13 |
Not clear |
| Cong Luo, Wen-Rui Ye, Wei Shi, Ping Yin, Chen Chen, Yun-Bo He, Min-Feng Chen, Xiong-Bin Zu, Yi Ca. Perfect match: mTOR inhibitors and tuberous sclerosis complex. Orphanet journal of rare diseases. vol 17. issue 1. 2022-03-05. PMID:35246210. |
perfect match: mtor inhibitors and tuberous sclerosis complex. |
2022-03-05 |
2023-08-13 |
human |